KR101098061B1 - 신생혈관형성 및/또는 증가된 혈관 투과성과 관련된 질병의치료에서 젬시타빈 및 임의로 이온화 방사선과 병용되는퀴나졸린 유도체 ｚｄ6474의 용도 - Google Patents

신생혈관형성 및/또는 증가된 혈관 투과성과 관련된 질병의치료에서 젬시타빈 및 임의로 이온화 방사선과 병용되는퀴나졸린 유도체 ｚｄ6474의 용도 Download PDF

Info

Publication number
KR101098061B1
KR101098061B1 KR1020057005960A KR20057005960A KR101098061B1 KR 101098061 B1 KR101098061 B1 KR 101098061B1 KR 1020057005960 A KR1020057005960 A KR 1020057005960A KR 20057005960 A KR20057005960 A KR 20057005960A KR 101098061 B1 KR101098061 B1 KR 101098061B1
Authority
KR
South Korea
Prior art keywords
gemcitabine
pharmaceutically acceptable
warm
acceptable salt
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020057005960A
Other languages
English (en)
Korean (ko)
Other versions
KR20050055070A (ko
Inventor
알란 바지
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20050055070A publication Critical patent/KR20050055070A/ko
Application granted granted Critical
Publication of KR101098061B1 publication Critical patent/KR101098061B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020057005960A 2002-10-09 2003-10-06 신생혈관형성 및/또는 증가된 혈관 투과성과 관련된 질병의치료에서 젬시타빈 및 임의로 이온화 방사선과 병용되는퀴나졸린 유도체 ｚｄ6474의 용도 Expired - Fee Related KR101098061B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0223380.7A GB0223380D0 (en) 2002-10-09 2002-10-09 Combination therapy
GB0223380.7 2002-10-09

Publications (2)

Publication Number Publication Date
KR20050055070A KR20050055070A (ko) 2005-06-10
KR101098061B1 true KR101098061B1 (ko) 2011-12-26

Family

ID=9945538

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057005960A Expired - Fee Related KR101098061B1 (ko) 2002-10-09 2003-10-06 신생혈관형성 및/또는 증가된 혈관 투과성과 관련된 질병의치료에서 젬시타빈 및 임의로 이온화 방사선과 병용되는퀴나졸린 유도체 ｚｄ6474의 용도

Country Status (22)

Country Link
US (2) US20060009418A1 (enExample)
EP (1) EP1551409B1 (enExample)
JP (2) JP5416328B2 (enExample)
KR (1) KR101098061B1 (enExample)
CN (1) CN100363004C (enExample)
AT (1) ATE357236T1 (enExample)
AU (1) AU2003269253B2 (enExample)
BR (1) BR0315088A (enExample)
CA (1) CA2501651C (enExample)
CY (1) CY1106601T1 (enExample)
DE (1) DE60312715T2 (enExample)
DK (1) DK1551409T3 (enExample)
ES (1) ES2282656T3 (enExample)
GB (1) GB0223380D0 (enExample)
IL (1) IL167633A (enExample)
MX (1) MXPA05003595A (enExample)
NO (1) NO330601B1 (enExample)
NZ (1) NZ538999A (enExample)
PT (1) PT1551409E (enExample)
SI (1) SI1551409T1 (enExample)
WO (1) WO2004032937A1 (enExample)
ZA (1) ZA200502753B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3522727B2 (ja) 1999-11-05 2004-04-26 アストラゼネカ アクチボラグ Ｖｅｇｆ阻害剤としてのキナゾリン誘導体
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
DE60121931T2 (de) 2000-04-07 2007-03-01 Astrazeneca Ab Chinazolinverbindungen
MX242553B (es) 2000-10-20 2006-12-06 Eisai Co Ltd Derivados aromaticos que contienen nitrogeno.
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
PL371486A1 (en) 2002-02-01 2005-06-13 Astrazeneca Ab Quinazoline compounds
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
NZ539408A (en) 2002-11-04 2007-09-28 Astrazeneca Ab Quinazoline derivatives as SRC tyrosine kinase inhibitors for treating solid tumours
MXPA05008583A (es) * 2003-02-13 2005-11-04 Astrazeneca Ab Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.
WO2004080462A1 (ja) 2003-03-10 2004-09-23 Eisai Co., Ltd. c-Kitキナーゼ阻害剤
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
WO2005004870A1 (en) * 2003-07-10 2005-01-20 Astrazeneca Ab Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
WO2006030826A1 (ja) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
MX2007003505A (es) * 2004-09-27 2007-05-10 Astrazeneca Ab Combinacion que comprende zd6474 e imatinib.
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
JP2009500384A (ja) * 2005-07-06 2009-01-08 アストラゼネカ アクチボラグ 併用療法
US20080219977A1 (en) * 2005-07-27 2008-09-11 Isaiah Josh Fidler Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
PL1971338T3 (pl) * 2005-12-22 2011-07-29 Astrazeneca Ab Połączenie ZD6474 i premetreksedu
AU2007252506C1 (en) 2006-05-18 2012-07-19 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
EP2065372B1 (en) 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
EP2066353B1 (en) * 2006-09-29 2013-01-02 AstraZeneca AB Combination of zd6474 and bevacizumab for cancer therapy
AU2008205847A1 (en) 2007-01-19 2008-07-24 Eisai R & D Management Co., Ltd. Composition for treatment of pancreatic cancer
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
AU2008325608B2 (en) 2007-11-09 2013-03-14 Eisai R & D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
US20120070368A1 (en) * 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
KR101677790B1 (ko) 2010-06-25 2016-11-18 에자이 알앤드디 매니지먼트 가부시키가이샤 키나제 저해 작용을 갖는 화합물의 병용에 의한 항종양제
KR101762999B1 (ko) 2011-04-18 2017-07-28 에자이 알앤드디 매니지먼트 가부시키가이샤 종양 치료제
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CA2889866A1 (en) 2012-12-21 2014-06-26 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
HRP20221047T1 (hr) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
CA2978226C (en) 2015-03-04 2025-02-18 Eisai R&D Management Co., Ltd. COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
MX381976B (es) 2015-08-20 2025-03-13 Eisai R&D Man Co Ltd Agente terapéutico contra tumores.
CN106727657A (zh) * 2016-12-27 2017-05-31 郑州郑先医药科技有限公司 一种治疗糖尿病的西药组合物及应用
CN106619688A (zh) * 2016-12-27 2017-05-10 郑州郑先医药科技有限公司 一种治疗糖尿病的药物组合物及应用
KR102539920B1 (ko) 2017-02-08 2023-06-05 에자이 알앤드디 매니지먼트 가부시키가이샤 종양-치료용 약제학적 조성물
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032651A1 (en) * 1999-11-05 2001-05-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1264738A (en) * 1984-12-04 1990-01-23 Eli Lilly And Company Treatment of tumors in mammals
US7132458B2 (en) * 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US6953679B2 (en) * 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
WO2004014383A1 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
MXPA05008583A (es) * 2003-02-13 2005-11-04 Astrazeneca Ab Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.
WO2005004870A1 (en) * 2003-07-10 2005-01-20 Astrazeneca Ab Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
MX2007003505A (es) * 2004-09-27 2007-05-10 Astrazeneca Ab Combinacion que comprende zd6474 e imatinib.
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
JP2009500384A (ja) * 2005-07-06 2009-01-08 アストラゼネカ アクチボラグ 併用療法
PL1971338T3 (pl) * 2005-12-22 2011-07-29 Astrazeneca Ab Połączenie ZD6474 i premetreksedu
EP2066353B1 (en) * 2006-09-29 2013-01-02 AstraZeneca AB Combination of zd6474 and bevacizumab for cancer therapy
US20100212978A1 (en) * 2009-02-23 2010-08-26 Wen-Hung Huang Bicycle with two operation molds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032651A1 (en) * 1999-11-05 2001-05-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 43, March 2002 (2002-3), pages 1080-1081 *

Also Published As

Publication number Publication date
WO2004032937A1 (en) 2004-04-22
NO330601B1 (no) 2011-05-23
CA2501651C (en) 2011-02-15
CN1703223A (zh) 2005-11-30
DE60312715D1 (de) 2007-05-03
NO20051575L (no) 2005-04-25
MXPA05003595A (es) 2005-06-03
CA2501651A1 (en) 2004-04-22
JP2006504723A (ja) 2006-02-09
CY1106601T1 (el) 2012-01-25
EP1551409B1 (en) 2007-03-21
CN100363004C (zh) 2008-01-23
AU2003269253B2 (en) 2007-04-05
ES2282656T3 (es) 2007-10-16
GB0223380D0 (en) 2002-11-13
AU2003269253A1 (en) 2004-05-04
HK1078771A1 (en) 2006-03-24
US20100120708A1 (en) 2010-05-13
ATE357236T1 (de) 2007-04-15
DE60312715T2 (de) 2007-12-06
NZ538999A (en) 2008-02-29
IL167633A (en) 2013-03-24
EP1551409A1 (en) 2005-07-13
BR0315088A (pt) 2005-08-16
DK1551409T3 (da) 2007-06-11
JP5416328B2 (ja) 2014-02-12
SI1551409T1 (sl) 2007-08-31
KR20050055070A (ko) 2005-06-10
US20060009418A1 (en) 2006-01-12
PT1551409E (pt) 2007-05-31
ZA200502753B (en) 2006-03-29
JP2011088921A (ja) 2011-05-06

Similar Documents

Publication Publication Date Title
KR101098061B1 (ko) 신생혈관형성 및/또는 증가된 혈관 투과성과 관련된 질병의치료에서 젬시타빈 및 임의로 이온화 방사선과 병용되는퀴나졸린 유도체 ｚｄ6474의 용도
KR20060033782A (ko) 백금 화합물 및 임의적으로 이온화 방사능과 조합된퀴나졸린 유도체 ｚｄ6474의 혈관신생 및/또는 증가된 혈관투과성 관련 질환 치료 용도
KR20070072543A (ko) Ｚｄ6474 및 이마티닙을 포함하는 병합법
KR20080079675A (ko) Ｚｄ6474 및 페메트렉시드의 조합물
EP1729808B1 (en) Combination therapy with azd2171 and 5-fu and/or cpt-11
KR20080077678A (ko) Ａｚｄ2171 및 페메트렉시드의 조합물
AU2006264620B2 (en) Combination therapy of cancer with AZD2171 and gemcitabine
KR20060130764A (ko) 병용 요법
HK1078771B (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of cancer
HK1096023B (en) Combination therapy with azd2171 and 5-fu and/or cpt-11

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20141126

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20151118

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20161123

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20171117

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20181115

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20191217

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20191217